POPULARITY
9 episodes with interventional oncology
11 episodes with interventional oncology
4 episodes with interventional oncology
4 episodes with interventional oncology
2 episodes with interventional oncology
2 episodes with interventional oncology
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here
What if a medical specialty society could drive groundbreaking research, fuel a global movement, and train the next generation of clinical investigators—all while tripling its membership in just five years? In a world of rapidly evolving cancer care, how can associations champion new modalities and build a community around transformative treatment approaches? In this episode of Associations Thrive, host Joanna Pineda interviews Jena Stack, Executive Director of the Society of Interventional Oncology (SIO). Jena discusses:How interventional oncology is emerging as the fourth pillar of cancer care, alongside surgery, chemotherapy, and radiation.How interventional oncologists use minimally invasive, image-guided techniques to target cancer with fewer side effects and faster recovery.How SIO has tripled in membership since 2020, growing from a small niche society to nearly 1,500 members globally.SIO's impressive governance model, which prioritizes relationship-building and alignment between the board and staff.How SIO is leading its own multi-million dollar clinical trials to address gaps in evidence and influence standards of care. Typically, this role has been reserved for pharma companies or academic institutions.The creation of the Clinical Trial Collaborative (CTC), a new research community and certificate program that trains and connects principal investigators.SIO's long-term vision to empower more physicians to lead studies and expand access to minimally invasive cancer treatments.The importance of "pausing to retreat" during growth, and how SIO balances ambition with sustainability.References:SIO Website
"... I can tell you I'd never do it again, but it showed that we can get interventional radiologists from around the world to come together and agree to do a trial, and actually execute the trial and get it done, and generate guidelines training data."—Michael Soulen, MD, FSIRIn this episode, part of the ongoing celebration of the Society of Interventional Radiology (SIR) 50th anniversary, host Nishita Kothary, MD, FSIR, speaks with longtime interventional oncology leader Michael Soulen, MD, FSIR, about the growth trajectory of the subspecialty, how SIR has evolved over the decades, and more.Related resources:View the society's 50th Anniversary celebration pageSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show
In this episode of Let's Talk MedTech, Omar chats with Jijo James, Chief Medical Officer for Johnson & Johnson MedTech and Interventional Oncology. James shares insights into J&J's commitment to patient safety, discussing how the company combines clinical safety, safety science, and bioethics to ensure safe and effective outcomes for patients. He highlights the importance of the operator in medical device procedures and how J&J is improving safety through innovative tools like the device briefing tool. James also discusses the challenges of device-related interruptions during surgeries, emphasizing the need for better communication and proactive strategies to avoid complications. This is a fascinating conversation for anyone interested in healthcare innovation and patient safety in the medtech industry!
Are you seeking to build your reputation and patient base within interventional oncology? In this episode, host Dr. Zachary Berman interviews Dr. Siddarth Padia, Dr. Tyler Sandow, Dr. Kavi Krishnasamy, and Dr. Kevin Burns about their journeys into interventional oncology (IO) and their experiences providing care in different practice settings. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125742 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The doctors begin by discussing how they became interested in interventional oncology, with most of them recognizing opportunities to address unmet needs in the field. Each guest shares insights on the timelines and challenges involved in starting their IO practices, which vary significantly today. For instance, telehealth clinics are particularly viable in private practice IO, thanks to conferencing software and virtual translators. Hybrid care models, which combine in-person and remote consultations, can help overcome patient-level barriers such as time and transportation. The panel also emphasizes how increased clinic availability can significantly drive growth in procedural volume. Finally, they offer advice for starting an IO practice, including the importance of having clinic support staff, building strong relationships with referring physicians, and staying up to date with new technologies. --- TIMESTAMPS 00:00 - Introduction 05:38 - Balancing Career Interests and Expectations 07:10 - Building an Interventional Oncology Practice 13:42 - Gaining Trust from Referring Physicians 17:33 - Importance of Open Communication 19:19 - Comparing Clinic Settings 26:01 - Essential Components of a Clinic 33:28 - Narrowing Your Interventional Practice 40:09 - Introducing New Technology --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf
"Clinical research is not cheap."Season 2 of the Association RevUP podcast celebrates the stories of associations who are utilizing business to bring about real change in their industries.In this debut episode, discover how the Society of Interventional Oncology and Jena Eberly Stack united multiple industry partners to fund a high-cost clinical trial with real-world health impacts. Then Dan Cole and Brittany Shoul share 5 ways your association can level up negotiations for your next big deal, no matter the size.About Association RevUP : Episodes are less than 20-minutes, written and produced to keep you engaged, and full of actionable insights. Hosted by Carolyn Shomali.- VPC, Inc., the production company PAR trusts with our in-person event the RevUP Summit, and the parter of this podcast.- MyPar.org: learn more about the PAR member community- RevUP Summit: November 4-6, 2025 in Annapolis, MD
Treatment of hepatocellular carcinoma (HCC), like that of many other cancers, spans a spectrum from curative to palliative intent. To explore the "grey zone" of treatment goals for intermediate-stage HCC patients, Dr. Sabeen Dhand interviews a panel of experts in the field: medical oncologists Dr. Adam Burgoyne and Dr. Lingling Du, along with interventional radiologists Dr. Kirema Garcia-Reyes and Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125739 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The discussion begins with an explanation of the Barcelona-Clinic Liver Cancer (BCLC) staging system. While this system takes into account helpful factors such as liver function, performance status, and tumor burden, it fails to fully capture the true heterogeneity of the HCC patient population. Additional considerations include tumor biology, response to previous treatments, and the location of metastases. The specialists then share their experiences in treating patients with comorbid gastrointestinal cancers and mixed tumors, discuss the benefits of an interventional oncology clinic setting, and highlight virtual opportunities for connecting with tumor boards. They also offer advice on patient education regarding treatment options. --- TIMESTAMPS 00:00 - Introduction to BCLC Staging 03:02 - Impact of Performance Status 06:29 - Predictors of Survival in HCC 09:51 - Palliative versus Curative Treatment Intent 13:55 - Comorbid and Mixed Gastrointestinal Cancers 16:51 - Adverse Effects of Treatment 20:37 - Interventional Oncology in the Clinic Setting 23:06 - Navigating Multiple Provider Viewpoints 28:01 - Complex Case Examples --- RESOURCES BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update (Reig et al, 2022): https://www.journal-of-hepatology.eu/article/S0168-8278(21)02223-6/fulltext CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf
In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. William Culp, a professor of soft tissue surgery at UC Davis specializing in surgical oncology and interventional radiology. Dr. Culp shares his journey into veterinary medicine, the role of mentorship in his career, and his groundbreaking work in interventional oncology. They explore the evolving use of interventional radiology as a "fourth pillar" in oncology, discussing treatments like urethral stenting, prostate embolization, and liver tumor therapies. Tune in for an enlightening discussion on how these minimally invasive techniques are transforming options for veterinary cancer care.
Cone Beam CT has become a cornerstone of modern interventional practice. Are you utilizing it to its fullest potential? Dr. Michael Miller joins host Dr. Chris Beck to discuss Cone Beam CT, sharing advanced techniques and clinical pearls. Dr. Miller is an interventional radiologist and Associate Professor of Radiology at Atrium Health, Wake Forest Baptist Hospital, North Carolina. --- This podcast is supported by: GE Healthcare Allia Image Guided Systems https://www.gehealthcare.com/products/interventional-image-guided-systems/allia --- SYNPOSIS Dr. Miller explains the importance of fundamental training and how fundamentals can be scaled across various procedures to improve outcomes, including vascular malformations and endoleaks. Dr. Miller then speaks to best practices that he has learned firsthand through his years of using Cone Beam CT. The doctors also touch on tips for setting up the IR suite and collaborating with anesthesia. --- TIMESTAMPS 00:00 - Introduction 07:22 - Advanced Uses of Cone Beam CT 15:04 - Setup and Best Practices 22:34 - Vascular Malformations 23:32 - Understanding Sclerosant Distribution 26:53 - Trajectory Guidance in Complex Cases 32:45 - Contrast Bolus Timing and Spin Techniques 40:16 - Advice for New Angio Suites --- RESOURCES BackTable VI Podcast Episode #51 - Cone Beam CT Techniques with Dr. Austin Bourgeois: https://www.backtable.com/shows/vi/podcasts/51/cone-beam-ct-techniques Shujaat, S., Alfadley, A., Morgan, N., Jamleh, A., Riaz, M., Aboalela, A.A., Jacobs, R., 2024. Emergence of artificial intelligence for automating cone-beam computed tomography-derived maxillary sinus imaging tasks. A systematic review. Clin Implant Dent Relat Res 26, 899–912. https://doi.org/10.1111/cid.13352 Orth, R.C., Wallace, M.J., Kuo, M.D., Technology Assessment Committee of the Society of Interventional Radiology, 2009. C-arm cone-beam CT: general principles and technical considerations for use in interventional radiology. J Vasc Interv Radiol 20, S538-544. https://doi.org/10.1016/j.jvir.2009.04.026 Bapst, B., Lagadec, M., Breguet, R., Vilgrain, V., Ronot, M., 2016. Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. Cardiovasc Intervent Radiol 39, 8–20. https://doi.org/10.1007/s00270-015-1180-6 Wallace, M.J., Kuo, M.D., Glaiberman, C., Binkert, C.A., Orth, R.C., Soulez, G., Technology Assessment Committee of the Society of Interventional Radiology, 2008. Three-dimensional C-arm cone-beam CT: applications in the interventional suite. J Vasc Interv Radiol 19, 799–813. https://doi.org/10.1016/j.jvir.2008.02.018 Bm, K., Sm, T., Mj, S., 2023. Cone-Beam CT With Enhanced Needle Guidance and Augmented Fluoroscopy Overlay: Applications in Interventional Radiology. AJR. American journal of roentgenology 221. https://doi.org/10.2214/AJR.22.28712 Kwok, Y.M., Irani, F.G., Tay, K.H., Yang, C.C., Padre, C.G., Tan, B.S., 2013. Effective dose estimates for cone beam computed tomography in interventional radiology. Eur Radiol 23, 3197–3204. https://doi.org/10.1007/s00330-013-2934-7
"'If we know activity, or sphere activity, at the time of delivery, and we know the dose to tumor, and we know the dose that we gave, we could figure out where the sphere concentrations are ... but we'd need to figure out what the dose to tumor is.' And he was like, 'Just do it in Simplicit90Y.' And at that point it was basically like, 'Oh, boom—just use the dosimetry tool we have to solve a problem. And so, that's where we are."—Tyler Sandow, MD In this Journal of Vascular and Interventional Radiology (JVIR) audio episode, lead author Tyler Sandow, MD, speaks with journal Managing Editor Ana Lewis about his November 2024 paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original article, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kelley Nunez, PhD, Richard Tramel, MD, Patrick Gilbert, MD, Brianna Oliver, MD, Michael Cline, MD, Kirk Fowers, PhD, Ari Cohen, MD, and Paul Thevenot, PhDRead the related commentary, "Known Unknowns: Gaps in Dose Distribution in Radioembolization, and in Our Understanding of Them," by A. Kyle Jones, MDRead the authors' response, "The Sphere Conundrum: Author's Reply to Commentary on Voxel-Based Dosimetry with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kirk Fowers, PhD, and Paul Thevenot, PhDSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show
Is your microwave ablation technique up to date? Dr. Ed Kim sits down with guest-host Dr. Kavi Krishnasamy to explore cutting-edge techniques in tumor ablation, with a focus on hepatocellular carcinoma (HCC) treatment with microwave. Dr. Ed Kim is the Director of Interventional Oncology and Professor of Radiology and Surgery in the Division of Vascular and Interventional Radiology at the Mount Sinai Medical Center. --- This podcast is supported by an educational grant from: Varian, a Siemens Healthineers company https://www.varian.com/ --- SYNPOSIS The doctors discuss microwave ablation, radiation segmentectomy, and the decision-making algorithms for choosing appropriate procedures based on lesion characteristics. Dr. Kim touches on the complexities of ablation near the diaphragm and subcapsular lesions, emphasizing the impact of practitioner skill and experience on outcomes. Recent advancements in ablation technologies, software, and device-specific versus device-agnostic applications are also highlighted, along with the importance of post-contrast scans and ultrasound skills. Dr. Kim also delves into emerging technologies such as HistoSonics, augmented reality/virtual reality, and immunotherapy synergies. The doctors underscore the need for a multidisciplinary approach for optimizing patient outcomes and pushing the field toward future innovations. --- TIMESTAMPS 00:00 - Introduction 04:28 - Standardizing Ablation Algorithms 07:51 - Suboptimal Lesion Locations 13:06 - Device Selection and Properties 22:49 - Ablation Planning Software 32:53 - Real-Time Visualization 44:48 - Biopsy and Ablation Techniques 52:14 - Future of Ablation Technology --- RESOURCES Dr. Ed Kim's Publications: https://scholars.mssm.edu/en/persons/edward-kim ACCLAIM Trial: https://www.sio-central.org/ACCLAIM-Trial A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4093 Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 SIR welcomes results of COLLISION Trial, presented at the 2024 ASCO Annual Meeting: https://www.sirweb.org/media-and-pubs/media/news-release-archive/collision-trial-06032024/ HistoSonics: https://histosonics.com/
Dr. Venkatesh Krishnasamy shares techniques and specific cases for challenging lung biopsies, his insights on mentorship, importance of multidisciplinary tumor boards, and the evolution of lung biopsy practices. Dr. Krishnasamy is an interventional radiologist and Director of Interventional Oncology at the University of Alabama Birmingham. --- CHECK OUT OUR SPONSOR Merit Biopsy Solutions https://www.merit.com/solutions/biopsy-solutions/ --- SYNPOSIS The doctors cover practical advice on handling complications like pneumothorax and hemoptysis, and share strategies for optimizing workflows to improve patient outcomes. Dr. Krishnasamy encourages listeners to leverage mentor experience and partake in continued learning to advance their practice. --- TIMESTAMPS 00:00 - Introduction 05:16 - Lung Biopsy Referrals and Multidisciplinary Approach 12:03 - Complex Lung Biopsies 25:43 - Needle Position Verification 27:29 - Importance of Cytopathologist Presence 28:51 - Blood Patching vs. Plug Technique 33:54 - Post-Procedure Protocols 36:15 - Advanced Techniques and Mentorship 44:26 - Handling Hemoptysis During Biopsies 47:50 - Encouragement for Trainees --- RESOURCES Society of Interventional Oncology: https://www.sio-central.org/ BackTable VI Podcast Episode #278 - Minimizing Complications for Lung Biopsies with Dr. Robert Suh: https://www.backtable.com/shows/vi/podcasts/278/minimizing-complications-for-lung-biopsies BackTable VI Podcast Episode #156 - Percutaneous Lung Biopsies: The Basics with Dr. Fred Lee (Part 1 of 2): https://www.backtable.com/shows/vi/podcasts/156/percutaneous-lung-biopsies-the-basics BackTable VI Podcast Episode #157 - Percutaneous Lung Biopsies: Pleural & Parenchymal Blood Patching with Dr. Fred Lee (Part 2 of 2): https://www.backtable.com/shows/vi/podcasts/157/percutaneous-lung-biopsies-pleural-parenchymal-blood-patching
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
CancerNetwork® spoke with Govindarajan Narayanan, MD about his practice becoming the first in the United States to successfully surgically treat a patient with a liver tumor using the Epione robot, as well as the process of transitioning from CT-based image guidance to the robotic workstation in his care.1 Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, both of Baptist Health South Florida, described how the use of Epione may save significant amounts of time while performing microwave ablation, cryoablation, and irreversible electroporation (IRE). Developers designed the robotic device to simplify several probe procedures, helping make large tumors more predictable to manage.2 According to Narayanan, Epione is suitable for use in any patient for whom his practice typically performs image-guided ablations. Additionally, the device may “level the playing field” by allowing those with less experience to give highly accurate surgery, thereby increasing the availability of physicians who can offer these treatments across multiple practices. Narayanan also described some of the potential challenges associated with adopting the Epione robot in clinic, such as adapting to the physical space that it occupies in the operating room. The device may also pose a steep learning curve with respect to procedures involving multiple needles such as cryoablation and IRE, as it is necessary to set a path that won't cause any deflections of the needle. Looking ahead, Narayanan said that future technological developments may allow users to operate the robot remotely, allowing patients to receive surgery at a treatment center even if a practicing physician is not physically present. “It's very exciting to be at the forefront of bringing such a cutting-edge technology to mainstream clinical practice,” Narayanan said. “Everything is done with one click, so it saves a significant amount of time. And because you're not doing multiple check scans when you place the needles, you're saving on radiation time.” References 1. First patient treated in the United States with Quantum Surgical's Epione® robot. News release. Quantum Surgical. May 24, 2023. Accessed November 6, 2023. https://shorturl.at/lzH01 2. Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6
Dr. Refky Nicola discusses future trends in Interventional Oncology with Dr. Stephen Solomon and Dr. Mohammad Elsayed. This episode is sponsored by Mayo Clinic. Interventional Oncology: 2043 and Beyond. Elsayed and Solomon. Radiology 2023; 308(1):e230139.
This recording features audio versions of September 2023 Journal of Vascular and Interventional Radiology (JVIR) abstracts:An Interim Analysis of the First 102 Patients Treated in the Prospective Vertebral Augmentation Sacroplasty Fracture Registry ReadEffectiveness and Safety of Intra-arterial Imipenem/Cilastatin Sodium Infusion for Patients with Hand Osteoarthritis–Related Interphalangeal Joint Pain ReadMiddle Meningeal Artery Embolization with Liquid Embolic Agents for Chronic Subdural Hematoma: A Systematic Review and Meta-analysis ReadDouble-Barrel Nitinol Stent Placement for Iliocaval Reconstruction: The Effect of Deployment Sequence and Direction on Final Configuration ReadRadioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma—A Prospective Feasibility Study ReadRobot-Assisted Transarterial Chemoembolization of Hepatocellular Carcinoma Using a Coaxial Microcatheter Driving Controller-Responder Robot System: Clinical Pilot Study ReadA 5-Year Update on the IR Residency Match: 2022 National Survey Results of Program Directors and Matched Applicants Compared with 2017 ReadJVIR and SIR thank all those who helped record this episode:Host:Rommell Noche, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAudio editor:Manbir Sandhu, University of California Riverside School of MedicineAbstract readers:Emily Barr, MBA, Burrell College of Osteopathic Medicine at New Mexico State UniversityJoy Achuonjei, MS, MBA, Zucker School of Medicine at Hofstra/Northwell, New YorkJoan Hwang, A.T. Still University School of Osteopathic Medicine, ArizonaChristopher Loiselle, MS, Lincoln Memorial University-DeBusk College of Osteopathic Medicine, TennesseeBenjamin Ellison, Medical University of South CarolinaJack Ficke, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAnne-Marie Nwajei, MS, Chicago Medical School at Rosalind Franklin University of Medicine and Science, Illinois © Society of Interventional RadiologySupport the show
This recording features audio versions of August 2023 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Percutaneous Cryoablation of Plasmacytomas: Oncologic Effectiveness and Adverse Events ReadThe Effect of Endovascular Treatment of Renal Artery Stenoses on Coexistent Aneurysms Associated with Fibromuscular Dysplasia ReadChange in Platelet Count after Transjugular Intrahepatic Portosystemic Shunt Creation: An Advancing Liver Therapeutic Approaches (ALTA) Group Study ReadTransjugular Intrahepatic Portosystemic Shunt and Thrombectomy (TIPS-Thrombectomy) for Symptomatic Acute Noncirrhotic Portal Vein Thrombosis ReadComparison between Suprapapillary and Transpapillary Uncovered Self-Expandable Metallic Stent Placement for Perihilar Cholangiocarcinoma ReadSafety and Effectiveness of Expandable Intravertebral Implant Use for Thoracolumbar Burst Fractures ReadJVIR and SIR thank all those who helped record this episode:Host:Rommell Noche, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAudio editor:Siddhi Hegde, MBBS, Massachusetts General Hospital Abstract readers:Colin Standifird, Kirk Kerkorian School of Medicine at University of Nevada, Las Vegas Khaleel Quasem, Michigan State University College of Human Medicine Ronnie Festok, Emory University School of Medicine, Georgia Jeremy Brown, DO, MS, Kaweah Health Medical Center, California Nicole Jisoo Kim, The Warren Alpert Medical School of Brown University, Rhode Island Jonathan Dzielski, Kansas City University, Missouri © Society of Interventional RadiologySupport the show
Dr. Jacob Fleming talks with Dr. Alan Alper Sag about building a musculoskeletal (MSK) interventions practice at Duke University Medical Center, collaborating with other specialists, and future predictions for MSK IR. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/o00BlF --- SHOW NOTES In this episode, our host Dr. Jacob Fleming interviews Dr. Alan Sag about building a musculoskeletal (MSK) interventions practice at Duke University Medical Center, collaborating with other specialists, and future predictions for MSK IR. Dr. Sag starts the episode by sharing his unique experience abroad. His first job was centered around helping to build an IR practice at a teaching hospital in Istanbul. This process helped him discover that the key to practice building was forming foundational cross-specialty relationships. These eventually led to more patient referrals and a higher level of care coordination. When he transitioned to an academic position, Dr. Sag first saw an unmet need in bone cryoablation. He recognized that IR procedures could be powerful alternatives to opioid escalation. A key turning point for his department came when a local TV station covered one of his patient's stories, and he saw a large increase in referrals. Dr. Sag emphasizes that it was important to ensure that the practice was set up with enough resources to accomodate a large volume of patients. Additionally, it was crucial to recognize when to say “no” to patients when a procedure was contraindicated for them. This patient-first approach also showed referring doctors that he was independently and objectively assessing patients, which helps with trust-building. As we move onto discussing multidisciplinary care, Dr. Sag says that learning another specialty's vocabulary can greatly enhance your communication and show your desire to collaborate. He encourages IRs to be flexible and learn which conditions are important to the referring doctors. When working with anesthesiology and PM&R, IRs can offer their services to enhance their pain palliation efforts. When working with oncologists, this pain palliation can allow cancer patients to continue participating in clinical trials. Finally, we discuss the next frontiers of MSK interventions. Dr Sag is excited by the prospect of standardization of MSK training, internally cemented screws, and vertebral body stents. --- RESOURCES Dr. Alan Sag Twitter: https://twitter.com/AlanAlperMD?s=20&t=8RGQsroHPZ9Vyc-0lpkiVQ Bone Cryoablation Media Coverage: https://www.wral.com/komen-s-kohl-tries-tumor-freezing-therapy-in-ongoing-cancer-fight/18974441/ Duke Center for Brain & Spine Metastasis: http://dukecancerinstitute.org/DCBSM SpineJack System: https://strykerivs.com/products/families/spinejack-system Society of Interventional Oncology (SIO): http://www.sio-central.org/ SIO's “Language of Oncology” Course: http://www.sio-central.org/p/cm/ld/fid=385 Visible Body Anatomy Atlas: https://www.visiblebody.com/anatomy-and-physiology-apps/human-anatomy-atlas e-Anatomy Atlas: https://www.imaios.com/en/e-Anatomy Ep. 199- Advanced Minimally Invasive Pain Interventions: https://www.backtable.com/shows/vi/podcasts/199/advanced-minimally-invasive-pain-interventions
In this episode of Boston Scientific Talks, Peter Pattison, President, Interventional Oncology, and Liza Davis, VP of R&D, Interventional Oncology, share insights into the acquisition of Obsidio and the integration of its unique gel embolic material technology into Boston Scientific's portfolio. The technology, described as a "conformable solid," offers a unique balance between a liquid and solid embolic, providing physicians with precise control and rapid occlusion during interventional oncology procedures. The discussion also covers the successful transition from FDA approval to commercialization, with Obsidio technology already being used in several cases. Looking ahead, Pattison and Davis discuss the potential for further applications of the technology and its integration with Boston Scientific's new coil products. This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.com/medical. Thank you for listening to the Boston Scientific Talks Podcast. Subscribe to this podcast on every major podcast platform.
In this episode we speak to Dr Jim Zhong who is an Academic Interventional Radiology Trainee in Leeds, currently completing a Cancer Research UK funded PhD in Prostate Cancer reirradiation techniques. He gives us an overview about the rapidly evolving field of Interventional Oncology and its potential to revolutionize cancer therapy. We also discuss his life as an academic interventional radiology trainee and the importance of conducting more high level research in IO to generate evidence to justify its use in the face of competition from other more established cancer treatments such as surgery, chemotherapy and radiation therapy.
A sub-speciality of interventional radiology, interventional oncology is common in human medicine, but is also gaining traction on the veterinary side. To outline this topic, Daniela Murgia, European Board of Veterinary Specialisation (EBVS)-recognised specialist in small animal surgery, joins the Vet Times Podcast. _____________________________
In this episode, host Aaron Fritts interviews engineer Lucien Blondel, co-founder and CTO of Quantum Surgical. We discuss robotic applications for interventional oncology procedures and the Epione robot's impacts on workflow and accuracy. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES Lucien first started innovating with robotics in the orthopedics, then neurosurgery fields. He has worked in startups and large corporations. Now, he is focused on interventional oncology. The catalyst for his idea came when his former startup was acquired. Lucien chose to create a company with three other co-founders and then explore. Quantum Surgical's mission is to democratize minimally invasive cancer treatment through pre-planning, advanced robotic assistance, and tumor ablation confirmation. Lucien started by obtaining the broad vision of the market. He noticed a clear unmet need: There was a proven clinical technique, but outcomes were very operator-dependent. Quantum Surgical's Epione robot could help alleviate this gap. Higher accuracy can lead to decreased invasiveness and more patient comfort in the outpatient setting. The first application for Quantum Surgical was pre planning software for interventional oncology procedures. He noticed that operators had difficulty visualizing masses for ablation. The robotic image vision software allows merging of CT and MRI images. Additionally, it can provide 3D modeling of ablation zones, map out needle trajectories, and confirm ablation by comparing pre-procedure and post-procedure imaging. Lucien emphasizes that the Epione robot can provide multiple functionalities for the same procedure, reducing the need to utilize different devices. The built-in features are programmed to adjust to patient movements and allow the physician to choose the safest path for needle placement. Finally, we discuss implications of robotics for workflow. Doctors can be more efficient in reviewing images, placing needles, and confirming ablation zones. Epione also reduces the need to obtain images during the procedure. At the moment, Epione is primarily focused on ablation of liver and kidney tumors. However, Lucien envisions the technology expanding to tumor biopsies, especially those that are located in high risk areas. Quantum Surgical is also looking into machine learning and prediction of local tumor progression. --- RESOURCES Quantum Surgical: https://www.quantumsurgical.com/epione/ Less Invasive Podcast: https://podcasts.apple.com/us/podcast/less-invasive/id1604673690 ROSA One Robot: https://www.zimmerbiomet.com/en/products-and-solutions/zb-edge/robotics/rosa-brain.html
In this episode, host Aaron Fritts interviews engineer Lucien Blondel, co-founder and CTO of Quantum Surgical. We discuss robotic applications for interventional oncology procedures and the Epione robot's impacts on workflow and accuracy. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES Lucien first started innovating with robotics in the orthopedics, then neurosurgery fields. He has worked in startups and large corporations. Now, he is focused on interventional oncology. The catalyst for his idea came when his former startup was acquired. Lucien chose to create a company with three other co-founders and then explore. Quantum Surgical's mission is to democratize minimally invasive cancer treatment through pre-planning, advanced robotic assistance, and tumor ablation confirmation. Lucien started by obtaining the broad vision of the market. He noticed a clear unmet need: There was a proven clinical technique, but outcomes were very operator-dependent. Quantum Surgical's Epione robot could help alleviate this gap. Higher accuracy can lead to decreased invasiveness and more patient comfort in the outpatient setting. The first application for Quantum Surgical was pre planning software for interventional oncology procedures. He noticed that operators had difficulty visualizing masses for ablation. The robotic image vision software allows merging of CT and MRI images. Additionally, it can provide 3D modeling of ablation zones, map out needle trajectories, and confirm ablation by comparing pre-procedure and post-procedure imaging. Lucien emphasizes that the Epione robot can provide multiple functionalities for the same procedure, reducing the need to utilize different devices. The built-in features are programmed to adjust to patient movements and allow the physician to choose the safest path for needle placement. Finally, we discuss implications of robotics for workflow. Doctors can be more efficient in reviewing images, placing needles, and confirming ablation zones. Epione also reduces the need to obtain images during the procedure. At the moment, Epione is primarily focused on ablation of liver and kidney tumors. However, Lucien envisions the technology expanding to tumor biopsies, especially those that are located in high risk areas. Quantum Surgical is also looking into machine learning and prediction of local tumor progression. --- RESOURCES Quantum Surgical: https://www.quantumsurgical.com/epione/ Less Invasive Podcast: https://podcasts.apple.com/us/podcast/less-invasive/id1604673690 ROSA One Robot: https://www.zimmerbiomet.com/en/products-and-solutions/zb-edge/robotics/rosa-brain.html
In this episode of Deserts to Mountaintops, Jessica interviews Cameron Curtis, author of the anthology chapter titled "The Sound of Resilience," where she details her desert to mountaintop experience. Deserts to Mountaintops is a limited series podcast created by Top 1% ranking podcast host, Jessica Kidwell, she lifts the author off the page as she holds conversations with co-authors of this inaugural anthology released in January 2023 by Soul Speak Press.This series is meant to give readers of DTM a deeper insight into the authors that brought their experiences to the page and hopes to inspire it's audience to a place of transformational healing.Deserts to Mountaintops: Our Collective Journey to (re)Claiming Our Voice is available now on Amazon.For more information on Deserts to Mountaintops, Soul Speak Press and upcoming anthologies, please visit www.desertstomountaintops.com. For more information Jessica Buchanan, please visit www.jessbuchanan.com or follow her on instagram at @jessicacbuchananMeet Cameron: Cameron Curtis is a classically trained musician. Was. Cameron's passion for music, beginning with piano and then vocal performance, began in middle school throughcollege where she graduated with a Bachelor of Arts with a concentration in musical theater and opera. It stops there. She met the love of her life, Scott, got married, moved to Northern Virginia, and bought a house at the age of 23.She lost her voice. Cameron's family life has always been solid. Her mother andfather gave her unconditional love and support regardless of the path she took. Both encouraged her to be authentic and strong. She had two strong-willed grandmothers who impressed upon her from an early age that you should always take advantage of opportunities, even if they seemed risky. Following that advice, she took a job as an executive assistant for a higher-education not-for-profit. From there she movedher way up the ladder from meeting planning to CEO. She discovered her true voice. Cameron is currently the President & CEO of C2 Association Strategies and has more than twenty-two years of not-for-profit management experience. She's led organizations such as the Association for Air Medical Services, MedEvacFoundation International, Society of Interventional Oncology, Association for Clinical and Translational Science, and the Texas Speech-Language Hearing Association. In addition, Cameron provided oversight for meetings and events, domestically and internationally. Cameron's passion for growing leaders and helping others find their voices shows in her willingness to take advantage of any opportunity that comes her way. Risk is exciting to her, and she lives by the mantra her grandmother taught her,“Never turn down anything but your coat collar.” Follow along on her website at www.c2associationstrategies.com or on Instagram and LinkedIn @cunzcurtis and Facebook at C2 Association Strategies.The theme song is courtesy of the The Mystic Chics.Instagram @themysticchics
In this podcast we speak to the guest editors of a BJR special feature on "The challenge of liver tumors for interventional oncology: past, present and future".
In this episode I discuss prostate cancer with Professor Mark Emberton, Consultant Urologist and Professor of Interventional Oncology. We discuss screening, diagnosis and treatment of prostate cancer.Link: https://prostatecanceruk.org/
In this crossover episode between BackTable VI and BackTable Innovation, Dr. Chris Beck interviews Dr. Riad Salem (Chief of Interventional Radiology at Northwestern University) and Peter Pattison (President of Interventional Oncology at Boston Scientific) about how TheraSpheres for Y90 radioembolization became a mainstay in the IR toolkit for HCC and where the technology is heading next. --- CHECK OUT OUR SPONSOR Reflow Medical https://www.reflowmedical.com/ --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/PvWJlD --- SHOW NOTES To begin, Peter outlines how the original concept of TheraSpheres began at the University of Missouri, as a collaboration between Drs. Delbert Day and Gary Ehrhardt, who combined their ceramic and nuclear chemistry expertises to create radioactive glass beads and published a paper in 1987. After animal and human testing, the product was licensed to the company Nordion, where Peter worked. The product was given a humanitarian device exemption (HDE) from the FDA, which allowed TheraSpheres to be used for investigational purposes. In the late 1990s, Dr. Salem was in his early interventional oncology career and heard about TheraSpheres. He recognized the enormous potential that this technology had to ensure known amounts of radioactive doses were delivered to the tumor and minimize adverse effects. In fact, he noticed that his Y90 patients had less pain, post-embolization syndrome, and hospitalization than his transarterial chemoembolization (TACE) patients. In the mid 2000s, he collected and submitted data to various conferences and journals, but he was met with criticism from the IR world, which was more comfortable with TACE, since it was the current standard of care. In 2011, Nordion decided to run a clinical trial, EPOCH, which eventually showed that the addition of TARE to systemic therapy for colorectal metastases to the liver led to longer progression free survival. Dr. Riad has focused his efforts on training more IRs on the methodology of Y90, since this was an important step to increasing adoption and minimizing missteps with the new technology. He believes that the advent of Y90 has resulted in better angiography, since IRs are more cognizant of off-target embolization. Dr. Salem also petitioned at the US Nuclear Regulatory Committee to allow IRs to become the authorized users for Y90 injection and advocated to add TARE to the National Comprehensive Cancer Network guidelines for liver cancer. Both of these developments allowed TARE to become more widely adopted. Finally, Peter discusses the competition that TheraSpheres has faced from TACE and SIRSpheres (resin-based radioembolization). He shares exciting new developments that have occurred since acquisition by Boston Scientific. These include exploration for the extra-hepatic use of TheraSpheres in glioblastoma and prostate cancer. --- RESOURCES BackTable Ep. 223- Portal Vein Recan #ReCanDoIt with Dr. Riad Salem: https://www.backtable.com/shows/vi/podcasts/223/portal-vein-recan-recandoit Therapeutic Use of 90Y Microspheres: https://pubmed.ncbi.nlm.nih.gov/3667306/ A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma: https://pubmed.ncbi.nlm.nih.gov/1327493/ Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up: https://pubmed.ncbi.nlm.nih.gov/7931662/ Humanitarian Device Exemption: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/humanitarian-device-exemption EPOCH Trial: https://ascopubs.org/doi/full/10.1200/JCO.21.01839 Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies: https://www.jvir.org/article/S1051-0443(07)60901-4/fulltext
In this crossover episode between BackTable VI and BackTable Innovation, Dr. Chris Beck interviews Dr. Riad Salem (Chief of Interventional Radiology at Northwestern University) and Peter Pattison (President of Interventional Oncology at Boston Scientific) about how TheraSpheres for Y90 radioembolization became a mainstay in the IR toolkit for HCC and where the technology is heading next. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/PvWJlD --- SHOW NOTES To begin, Peter outlines how the original concept of TheraSpheres began at the University of Missouri, as a collaboration between Drs. Delbert Day and Gary Ehrhardt, who combined their ceramic and nuclear chemistry expertises to create radioactive glass beads and published a paper in 1987. After animal and human testing, the product was licensed to the company Nordion, where Peter worked. The product was given a humanitarian device exemption (HDE) from the FDA, which allowed TheraSpheres to be used for investigational purposes. In the late 1990s, Dr. Salem was in his early interventional oncology career and heard about TheraSpheres. He recognized the enormous potential that this technology had to ensure known amounts of radioactive doses were delivered to the tumor and minimize adverse effects. In fact, he noticed that his Y90 patients had less pain, post-embolization syndrome, and hospitalization than his transarterial chemoembolization (TACE) patients. In the mid 2000s, he collected and submitted data to various conferences and journals, but he was met with criticism from the IR world, which was more comfortable with TACE, since it was the current standard of care. In 2011, Nordion decided to run a clinical trial, EPOCH, which eventually showed that the addition of TARE to systemic therapy for colorectal metastases to the liver led to longer progression free survival. Dr. Riad has focused his efforts on training more IRs on the methodology of Y90, since this was an important step to increasing adoption and minimizing missteps with the new technology. He believes that the advent of Y90 has resulted in better angiography, since IRs are more cognizant of off-target embolization. Dr. Salem also petitioned at the US Nuclear Regulatory Committee to allow IRs to become the authorized users for Y90 injection and advocated to add TARE to the National Comprehensive Cancer Network guidelines for liver cancer. Both of these developments allowed TARE to become more widely adopted. Both of our guests highlight the importance of focusing on patient outcomes and letting long term data prove efficacy. Finally, Peter discusses the competition that TheraSpheres has faced from TACE and SIRSpheres (resin-based radioembolization). He shares exciting new developments that have occurred since acquisition by Boston Scientific. These include exploration for the extra-hepatic use of TheraSpheres in glioblastoma and prostate cancer. --- RESOURCES BackTable Ep. 223- Portal Vein Recan #ReCanDoIt with Dr. Riad Salem: https://www.backtable.com/shows/vi/podcasts/223/portal-vein-recan-recandoit Therapeutic Use of 90Y Microspheres: https://pubmed.ncbi.nlm.nih.gov/3667306/ A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma: https://pubmed.ncbi.nlm.nih.gov/1327493/ Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up: https://pubmed.ncbi.nlm.nih.gov/7931662/ Humanitarian Device Exemption: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/humanitarian-device-exemption EPOCH Trial: https://ascopubs.org/doi/full/10.1200/JCO.21.01839 Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies: https://www.jvir.org/article/S1051-0443(07)60901-4/fulltext
Dr. Jacob Fleming talks with Dr. Alan Alper Sag about building a musculoskeletal (MSK) interventions practice at Duke University Medical Center, collaborating with other specialists, and future predictions for MSK IR. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES In this episode, our host Dr. Jacob Fleming interviews Dr. Alan Sag about building a musculoskeletal (MSK) interventions practice at Duke University Medical Center, collaborating with other specialists, and future predictions for MSK IR. Dr. Sag starts the episode by sharing his unique experience abroad. His first job was centered around helping to build an IR practice at a teaching hospital in Istanbul. This process helped him discover that the key to practice building was forming foundational cross-specialty relationships. These eventually led to more patient referrals and a higher level of care coordination. When he transitioned to an academic position, Dr. Sag first saw an unmet need in bone cryoablation. He recognized that IR procedures could be powerful alternatives to opioid escalation. A key turning point for his department came when a local TV station covered one of his patient's stories, and he saw a large increase in referrals. Dr. Sag emphasizes that it was important to ensure that the practice was set up with enough resources to accomodate a large volume of patients. Additionally, it was crucial to recognize when to say “no” to patients when a procedure was contraindicated for them. This patient-first approach also showed referring doctors that he was independently and objectively assessing patients, which helps with trust-building. As we move onto discussing multidisciplinary care, Dr. Sag says that learning another specialty's vocabulary can greatly enhance your communication and show your desire to collaborate. He encourages IRs to be flexible and learn which conditions are important to the referring doctors. When working with anesthesiology and PM&R, IRs can offer their services to enhance their pain palliation efforts. When working with oncologists, this pain palliation can allow cancer patients to continue participating in clinical trials. Finally, we discuss the next frontiers of MSK interventions. Dr Sag is excited by the prospect of standardization of MSK training, internally cemented screws, and vertebral body stents. --- RESOURCES Dr. Alan Sag Twitter: https://twitter.com/AlanAlperMD?s=20&t=8RGQsroHPZ9Vyc-0lpkiVQ Bone Cryoablation Media Coverage: https://www.wral.com/komen-s-kohl-tries-tumor-freezing-therapy-in-ongoing-cancer-fight/18974441/ Duke Center for Brain & Spine Metastasis: http://dukecancerinstitute.org/DCBSM SpineJack System: https://strykerivs.com/products/families/spinejack-system Society of Interventional Oncology (SIO): http://www.sio-central.org/ SIO's “Language of Oncology” Course: http://www.sio-central.org/p/cm/ld/fid=385 Visible Body Anatomy Atlas: https://www.visiblebody.com/anatomy-and-physiology-apps/human-anatomy-atlas e-Anatomy Atlas: https://www.imaios.com/en/e-Anatomy Ep. 199- Advanced Minimally Invasive Pain Interventions: https://www.backtable.com/shows/vi/podcasts/199/advanced-minimally-invasive-pain-interventions
Dr. Onik talks with Rachel and Jamison Dye, founders of The Cancer Box, a resource designed by cancer survivors to empower others on their journey from victim to victor. But before The Cancer Box was born, there was the cancer. In 2018 Rachel and Jamison were living an idyllic life in Washington state with their growing family. An avid runner, Rachel went for her usual five-mile run around the lake, a route she'd been running since she was a teenager. Two days later, in sudden and tremendous pain, she was rushed to the ER and admitted for emergency surgery. Rachel had a golf-ball sized tumor removed from her colon, woke up with a colostomy, and for several days awaited test results. The verdict? Metastatic Stage IV Colon Cancer. The 27-year-old mother of three was told she may only have six months to live. Not only did Rachel and Jamison not fully understand the diagnosis, but they also knew little about cancer. “The first thing we did was just breath,” recalls Jamison. Next, they called Rachel's parents and their pastors. The couple intuitively knew they had to take some time to decide how to move ahead, but the pressure to act quickly given a death-sentence-diagnosis is tremendous. They didn't just want a physical treatment plan; they wanted a spiritual and emotional plan too. The hope they lacked came from a nurse who told them of someone she knew who beat the same cancer and Rachel leaned into her belief that she would live. Dr. Onik and the Dyes discuss some KEY COMPONENTS of their strategy: ++ Determining who'll be on your “team” ++ The importance of “soul-care”? ++ How to choose an oncologist ++ Diving into the research ++ Becoming your own advocate ++ Building a nutrition plan specific to your body's physiology ++ Learning to navigate emotional trauma Jamison, a project manager by trade, began doing the research and building the support team while Rachel recovered from surgery. The couple continued to follow their own path, emphasizing the importance of prayer, trusting themselves and God. One day at a time, Rachel made progress, healing in many areas of her life. After Rachel entered remission, the couple began processing all they'd been through. They had amassed loads of information and began wondering, “What does life look like now?” The Cancer Box was born. The couple decided to lean further into their experience and create the resource they wished they'd had on their journey. Already being peppered with questions from others battling cancer they knew they had developed a knack for coming up with meaningful solutions. The Cancer Box is a monthly subscription of tools and resources for the body (e.g., vitamins, snacks), mind (how to handle side effects) and soul (uplifting reading material) to empower people to take charge of own their care or aid someone they love. The Dyes experience has brought them something unexpected that they deeply cherish—an even closer relationship to God. Dr. Onik too has no doubt that he was given cancer to prove a point (although he says he didn't like it at the time) and that is, prayer combined with his unique treatment DO WORK! Remarkably, Rachel says she wouldn't change it. “Even if I could undo my cancer, I wouldn't because I can see how God was using it in our lives and our marriage and our family to refine and change my heart.” Rachel has been cancer-free for over a year. Dr. Onik wraps up by answering your questions. To submit a question to the Mailbag, use the contact page on Dr. Onik's website. *** To learn more visit https://www.thecancerbox.com/ Facebook | YouTube | Instagram @the_cancer_box *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. GARY ONIK https://garyonikmd.com/ CHECK OUT all our inspiring podcasts at https://www.lifestough.com/
Dr. Onik talks candidly with internationally celebrated recording artist, composer, concert pianist and radio/television personality, John Tesh. His Intelligence for Your Life radio show currently airs on 350 stations and reaches 14 million people each week and his memoir, Relentless: Unleashing a Life of Purpose, Grit, and Faith is now available wherever books are sold. These two men have more in common than you might think. Both had incurable cancer. Both turned to their faith for healing. Both are composers—Tesh of music and Onik of cancer treatments. They are both saving lives in different ways, allowing the Divine to work through them. Like many cancer patients, Tesh's journey with the disease began with receiving the gut blow prostate cancer diagnosis, which completely blindsided him and his wife of thirty years, Connie Sellecca. After a series of tests and biopsies, a doctor told him he'd better “get his affairs in order.” But with a background in research, it seemed like the best approach was to absorb themselves in learning as much as they could about surviving prostate cancer. As a result, he tracked down an expert, Dr. Ted Shaeffer, and was on his way to Johns Hopkins with some much-needed hope. As a Christian, Tesh's faith was a deep well for him to draw from, but it wasn't until he was given the devastating news that his cancer had returned that he discovered the Bible's teaching on Diving Healing. At the beginning of his journey his focus was on getting the cancer out of his body as fast as possible, understandably. When the cancer returned, this time in other areas of his body, the allopathic recommended course of action was a form of radiation treatment that would have impaired several of his bodily functions. The Teshs said, “No thanks,” and began to stand on God's promises. But the journey has not been without struggle. At one point Tesh took up drinking and using drugs to deal with his terminal diagnosis, until his wife said if he was giving up, then so was she. It was a sobering wakeup call. Several scriptures took on new meaning for him including Mark 11:23 and Proverbs 18:21 which says, “Life and death are in the power of the tongue.” Thanks to what Tesh had learned from quantum physics he knew the power of words. He credits Connie for speaking life over him and helping his faith to grow. On the other hand, once he discovered the Word's healing power, his pride in standing on his faith alone almost killed him after he refused other treatments. Eventually he realized that all healing modalities can be used together for good. Dr. Onik was at one time an empiricist—and atheistic scientist. But he continued to see miracles, patients opting for no treatment only prayer and being healed, for example. His eyes were opened and thankfully so. After having scans to find out what was going on in his own body, Dr. Onik diagnosed his own terminal metastatic prostate cancer. He was dealt the same blow. But he knew he was in God's hands and within just hours he'd planned out his own treatment. Prayer was an integral part of his plan. “Every cancer type is really specific…But the one thing you can add to any cancer regiment is prayer.” Dr. Onik believes the best course of treatment often encompasses multiple modalities. There are now excellent and extremely reliable ways of using new treatments such as focal therapy and cryo-ablation. Dr. Onik's complete recovery included a surgical treatment of his own invention, along with prayer. Tesh's experience was similar, using conventional cancer protocols along with prayer and lifestyle changes. Tesh's journey took him to a new level of understanding of suffering, and its role in life. The two men also agree on the importance of humor, and both have learned to view life's circumstances through a more light-hearted lens. Dr. Onik gives his advice to those who have received a cancer diagnosis about what to do in the next 24 hours. Tesh shares what he does to remain positive. His latest venture, TeshTV, draws on his extensive archive of motivational, inspirational and healing music, videos and messages to help others. The ‘pay what you feel' subscription provides daily, live programming available on all devices. Dr. Onik wraps up by answering your questions. To submit a question to the Mailbag, use the contact page on Dr. Onik's website. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. GARY ONIK https://garyonikmd.com/ CHECK OUT all our inspiring podcasts at https://www.lifestough.com/
Role of Interventional Oncology in Colorectal Cancer with guest Dr. David Madoff March 13, 2022 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Role of Interventional Oncology in Colorectal Cancer with guest Dr. David Madoff March 13, 2022 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Role of Interventional Oncology in Colorectal Cancer with guest Dr. David Madoff March 13, 2022 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
In this episode Dr. Gary Onik reveals the five things he believes everyone needs to know to survive cancer. An integrated oncologist and a pioneer in the field of cancer treatment for over 40 years, you could say Dr. Onik knows his subject front to back. But he's also a cancer survivor, ironically of the very cancer he specializes in, advanced metastatic prostate cancer. He's alive and well with no evidence of disease and wants to help others every day he lives. “This is NOT about getting ready to die, it's about lessening your anxiety…because your anxiety and your mental processes have a direct effect on your immunology.” Dr. Gary Onik Get Dr. Onik's advice on… 1—Finding the RIGHT oncologist for YOU, what to look for and how to conduct the research. 2—Taking responsibility for your own care, advocating for yourself, and researching outside the usual protocols including clinical trials. 3—Why YOU need the support of your loved ones and why THEY NEED to provide it. 4—The power of mobilizing as many people to pray for you as possible. Prayer works. 5—Finding comfort in faith and a higher power and accepting that some things are beyond understanding. Dr. Onik closes with two things that help us successfully overcome when life's tough: Purpose and Faith. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. GARY ONIK https://www.garyonik.com/ CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/
Just as the specialty is innovative, we foster a culture where we want to be innovative. And we want to be nimble, just as our members are nimble. And so when we look at the DNA of how we operate, we kind of say, "This is how you practice ... This is the way that we want to operate, as well." —Keith Hume, SIR Executive DirectorIn a special year-end review, Warren Krackov, MD, FSIR, speaks with SIR Executive Director Keith Hume and SIR Direction of Publications Brian Haefs about the top stories impacting interventional radiology in 2021 and what 2022 may bring. Plus, we share excerpts from the three most downloaded IR Quarterly articles of the year: TACE and immunotherapy for intermediate-stage HCCThe macro effects of microaggressionsGenicular artery embolization: The future standard of care for inflammatory conditionsNote: This episode was recorded on Jan. 13, 2022.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show (https://www.sirweb.org/corporate-gateway/advertising/)
“I felt helpless, but I just prayed and prayed and prayed.” Lisa Dr. Onik talks to Senior Executive Producer of the Emmy®-winning newsmagazine “Extra,” now in its 28th season, Lisa Gregorisch-Dempsey, who experienced an incredible spiritual transformation during her husband's health crisis. Lisa had a typical Jewish upbringing in New Jersey, but her media career took her all over the country, having spent most of her career in California. One night, taking a call in her office at Extra, dressed in a gown about to attend the Emmys, she abruptly did an about face toward home. Her husband Gary had been told he had cancer on the back of his tongue. From Gary's unexpected heart surgery to radiation to chemo, Lisa began praying in her car, and reading Christian author Max Lucado for the peace it brought her. Then she started reading the New Testament. Gary fully recovered and didn't seem to mind when Lisa read him passages from the Bible, having grown up Methodist, but converted to Judaism when they married. But it wasn't until Gary got a call years later learning that the cancer had metastasized to his lung that he also got on the prayer wagon. Today, alive and well, the couple remarkably have dedicated their lives to Jesus. They never miss a day of their early morning ritual together, spending time with God. Dr. Onik asks Lisa, also known as the Doctor Whisperer, has your Christianity ever made you uncomfortable or affected your career? Lisa is quick to respond, “Not even for one second. I have a big forum to help other people,” and she uses it to spread hope. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. GARY ONIK https://www.garyonik.com/ CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/
“Mother Nature doesn't really care about our patent system. Things work or they don't work.” Dr. Ralph Moss Dr. Moss continues telling his story of the Memorial Sloan Kettering Laetrile coverup, his early experience with challenging the medical establishment and the personal and professional costs of telling (and not telling) the truth. Dr. Moss reveals the way drugs come to market and why so many treatments that can help patients aren't prescribed, let alone make the headlines. So, when the day came that Dr. Moss was MISTAKENLY told that he had advanced metastatic prostate cancer and there was nothing that could be done for him, how did he respond? Listen for the happy ending! *** DR. RALPH MOSS & MOSS REPORTS https://www.mossreports.com/ IMMUNOTHERAPHY: THE BATTLE WITHIN | 2020 DOCUMENTARY https://immunotherapyfilm.com/ SECOND OPINION | 2014 DOCUMENTARY https://www.secondopinionfilm.com/ *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. DR. GARY ONIK https://www.garyonik.com/ CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/
“I'm coming up on my 50th year anniversary of my time as a science writer, writing almost exclusively about cancer...And I'll tell you, it gets more and more interesting.” Dr. Ralph Moss A graduate of NYU and Stanford University, medical writer Dr. Ralph Moss has been independently evaluating the claims of conventional and non-conventional cancer treatment for the past 35 years. But before he began writing books, he helped to leak the truth about an esteemed scientist's research on a drug that could block cancer metastasis—when his bosses wanted him to lie. [More on that in Part 2!] In Part 1 of this gripping conversation Dr. Moss talks about getting his start in medical research and writing, landing a job at the prestigious Memorial Sloan Kettering Cancer Center. He sheds light on why oncologists treat patients with “cookbook methods,” the tremendous pressure on doctors not to deviate from medical guidelines and the connection between a doctor's treatment plan and your insurance company. His passion for helping people overcome cancer is clear. As a cancer survivor himself, he knows well the importance of his work. LISTEN TO PART 2 of the conversation to learn THE SHOCKING TRUTH and WHAT IT COST. *** DR. RALPH MOSS https://www.mossreports.com/ *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. DR. GARY ONIK https://www.garyonik.com/ CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/
The vascular and interventional radiology department at RUSH University Medical Center provides the most current and clinically comprehensive care to patients. Several of Rush's internationally renowned interventional radiologists have helped to pioneer and advance many interventional techniques used today. By performing the latest procedures and engaging in advanced research, our providers are working to uncover new uses for interventional radiology approaches as well as refine current techniques, in specialties such as oncology, peripheral arterial disease and women's health. Jordan Tasse, MD, an interventional radiologist at RUSH University Medical Center, profiles the cutting edge procedures performed through interventional radiology care at RUSH. As one of the few places nationwide to provide the full spectrum of vascular and interventional procedures, interventional radiology care at RUSH has transformed the lives of many of its patients, particularly those affected by cancer. Dr. Tasse is also the Director of Interventional Oncology at RUSH and is an Associate Professor of Radiology and Vascular and Interventional Radiology at RUSH Medical College. “We have a really great atmosphere of collaboration between different specialties. Our approach is grounded in a multidisciplinary fashion where we have medical oncologists, hepatologists, liver surgeons, colorectal surgeons, radiation oncologists, and interventional oncologists all talking at multidisciplinary tumor boards and developing the best approach to each patient's cancer care.” CME credit link: https://cmetracker.net/RUSH/Publisher?page=pubOpenSub#/event/484420
SURVIVING CANCER—Is the mind-body connection real? “Every cell in your body is listening to your brain…I think a big part of cancer survival is believing there is a better path.” Jeff Olson According to Dr. Onik, Jeff Olson is a modern Renaissance man—entrepreneur, author, publisher, and member of the Happiness Hall of Fame. He's also a prostate cancer survivor who knows when life is going great, how it feels to be told you have cancer. “I felt betrayed because I'm very healthy in my diet and lifestyle,” Jeff says of his diagnosis. He knew that his solution would need to allow him to live without obliterating his life. For Jeff, the spiritual aspect of healing was just as important as having the support of family and friends. Dr. Onik reveals the one aspect of prostate cancer that he finds heinous is the lack of information patients get about radical prostatectomy and the positive margin. It's so important for patients to do their own research and find treatment options that work for them. Going against mainstream medical advice is difficult. Anxieties and fears affect the immune system and spiritual grounding can help you remain calmer and heal better. You'll be challenged to consider these critical life questions: What do you allow your conscious brain to think? How do your BELIEFS influence your HEALTH? Who do you associate with? How do miracles happen? What's the power of prayer, scientifically? After a cancer diagnosis it might be time to reconsider why it's said, “There are no atheists in the foxholes.” *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. TO CONTACT DR. ONIK visit https://www.garyonik.com/. CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/.
NUTRACEUTICALS VS. PHARMACEUTICALS—This podcast could save your life. Dr. Russell Blaylock, retired neurosurgeon and author of Natural Strategies for Cancer Patients and his monthly newsletter, The Blaylock Wellness Report, with over 100,000 subscribers shares his lifesaving knowledge and expertise on the use of nutraceuticals and why they aren't more common in treatment, particularly cancer treatment. For Dr. Onik and Dr. Blaylock, the medical establishment isn't accepting these new treatments as rapidly as they would like for the good of their patients. Listen to find out why. Dr. Blaylock's own interest in alternative treatments arose because he was disappointed in results using chemotherapy, which oftentimes makes the outcome for the patient worse by doing damage to healthy cells, thereby increasing the likelihood of secondary cancers. However, you see the opposite with natural substances and immunotherapy. The science behind these treatments is so sophisticated now that the orthodox medical community cannot ignore it. In fact, combining low dose chemo with nutraceuticals yields better results than higher dose chemo—and patients feel better while undergoing treatment. The best weapon against cancer that we have is immunotherapy. Immune cells can destroy virtually every cancer and every cancer cell in every case if we learn how to properly harness it. We're just now rediscovering what was known a hundred years ago. Listen as Dr. Blaylock Reveals… What He Thinks of Supplements The POWER of Observational Medicine Fraudulent Behavior in the Pharmaceutical Industry The “MAGIC” and SCIENCE Behind Natural Treatments How to Find and Oncologist with Views Compatible with Your Own The Role of God, Prayer and Faith in Healing Dr. Blaylock's book is available where most books are sold. To learn more or subscribe to his newsletter visit https://www.blaylockreport.com/. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. TO CONTACT DR. ONIK visit https://www.garyonik.com/. CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/.
The Challenges and Benefits of Doing Things Differently “I haven't had a sick day since I was diagnosed.” Dr. Howard Freedman Dr. Howard Freedman is a retired pediatric ophthalmologist renowned for inventing a way to screen children as young as 6 months for amblyopia, lazy eye, one of the most prevalent—yet preventable—causes of blindness in children. He's also been diagnosed with cancer, twice. In this episode he talks about the obstacles he faced while trying to make inroads within the medical community to help kids who would otherwise unnecessarily lose their vision, a true healthcare tragedy. And he shares his cancer story. Two journeys, one professional and the other personal, have surprising parallels. These two physicians share important REVELATIONS in: The forces that try to stop therapeutics that really help people The basic problem with medicine when trying to change the status quo Seeking multiple opinions and exploring those with a doctor you trust Choosing treatments that allow for a normal lifestyle Dr. Onik shares his Medical Golden Rule perhaps the single greatest factor owing to his incredible success. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. TO CONTACT DR. ONIK visit https://www.garyonik.com/. CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/.
CAREGIVING—How do I do this as well as I can? There are 53 million caregivers in the United States, probably a lot more. If you know one or should you suddenly find yourself as one, you need to hear Dr. Onik's conversation with Karen Warner Schueler, author of the transformative book “The Sudden Caregiver: A Roadmap for Resilient Caregiving.” This is also a conversation for medical professionals, especially in the oncology field. Her book is filled with ideas, encouragement, and resources so you can also take care of yourself. After all, the better the caregiver, the better the care receiver. After raising a family and reaching a comfortable stage of life, looking forward to their future together, Karen's husband went to his doctor for a ‘bad back' and came out with a stage 4 cancer diagnosis. Thrust into the role of caregiver, depleted and vulnerable, she found resources lacking. So, she wrote the book she wanted to read—to help caregivers write their own story. Learn from Karen… The Paradox of Caregiving Where to find REAL hope The Pathways to Wellbeing Who needs to work at empathy FIND links to organizations that provide local, national, and international caregiver support under the “Resources” tab on her website http://thesuddencaregiver.com. *** For over 40 years Dr. Gary Onik has been pioneering advances in cancer treatment that have rocked the field of oncology, inventing an entirely new branch of cancer treatment now known as “Interventional Oncology” based on his innovative minimally invasive techniques. Both doctor and patient, he created a cancer vaccine and successfully treated his own terminal prostate cancer using his invention. In addition to his medical practice, Dr. Onik is an Adjunct Professor of Mechanical Engineering at Carnegie Mellon University, working closely with his colleagues to develop the next generation of cancer fighting technologies. His latest work, using immunotherapy to treat metastatic cancer, offers hope to those patients with literally no other options. TO CONTACT DR. ONIK visit https://www.garyonik.com/. CHECK OUT all our inspiring podcasts visit https://www.lifestough.com/.
Cancer is Tough, but YOU are TOUGHER! is hosted by Dr. Gary Onik, adjunct professor of Mechanical Engineering at Carnegie Mellon University and former professor of Neurosurgery at the Medical College of Pennsylvania. Dr. Onik pioneered image guided tumor ablation, an invention that has saved the lives of 10's of thousands of patients and initiated a 4th branch of cancer treatment called “Interventional Oncology.” He introduced with Prof. Boris Rubinsky the “Nanoknife,” an electrical method for treating pancreatic cancer that can't be surgically removed, which has been shown to double the life expectancy in this patient population and created a simple way of making a cancer vaccine out of a patient's own tumor and successfully treated his own terminal prostate cancer using this invention. Join Dr. Onik as he explores the intersection of the mind, body and the spiritual and its relationship to sickness and healing, specifically cancer. Coping with it, pursuing the best treatment for you and helping your partner/family/friend moving forward. Dr. Onik's podcast is uniquely personal. Rather than focusing on advances in technology and clinical therapies, he explores the heart of a patient's and family's cancer journey. He delves into the inner emotional and spiritual resources patients and loved ones need to address, deep concerns such as: Choosing a treatment strategy that harmonizes with their worldview and life's goal Grappling with traditional state-of-the-art vs. outside-the-box options Finding the meaning of cure vs. healing This podcast is for anyone whose life has been touched by cancer.
On Health Suites, Interventional Oncology or IO is a procedure that benefits cancer patients due to its minimally invasive option that enables the safe and effective treatment of cancer patients. Claressa Monteiro speaks with Associate Professor Tay Kiang Hiong, Head and Senior Consultant, Vascular and Interventional Radiology, SGH,to find out more. See omnystudio.com/listener for privacy information.
La chirurgia moderna ha posto molta attenzione a limitare al minimo le cicatrici, interne ed esterne, lasciate da un'operazione chirurgica, e per questa ragione molte di esse oggi si effettuano per mezzo di lunghe sonde dotate di piccoli arnesi sulla punta, con cui si interviene agendo di fino, spesso supportati da robot chirurgici. Ma si vorrebbe andare oltre, cioè verso sistemi di navigazione tridimensionale all'interno del corpo umano, grazie ai quali il medico è possa vedere "attraverso" il paziente più o meno come siamo abituati a immaginare che sia in grado di fare superman. Un esempio di questo approccio è quanto ha messo a punto RAW-Endosight. La Start-up, di cui facciamo la conoscenza in questa puntata, ha realizzato un sistema che potrebbe spianare la strada a una tecnica chirurgica oggi praticata di rado chiamata Interventional Oncology, che consiste nel raggiungere con precisione millimetrica un tessuto tumorale per poi distruggerlo col calore. Ospite Alessandro Rotilio, CEO RAW-Endosight e imprenditore seriale
Ep. 92 Interventional Oncology in Private Practice- Part II Approach to HCC with Dr. Justin Lee by BackTable
Ep. 91 Interventional Oncology in Private Practice- Part I Practice Building with Dr. Justin Lee by BackTable
In this podcast, we speak to Dr Thomas Helmberger, author of a recent BJR Review on “The evolution of interventional oncology in the 21st century”.
This episode is all about maps! We're bringing you the glamour of prostate imaging, decoding a document of hidden histories from Northern Ireland and learning how maps can protect forests around the world. Join our host, Suzie McCarthy, as she explores these topics with three UCL researchers: Mark Emberton, Dean of Faculty of Medical Sciences and Professor of Interventional Oncology; Tim Weyrich, Professor of Visual Computing in the Virtual Environments and Computer Graphics group in the Department of Computer Science; and Jerome Lewis, Lecturer in the Department of Anthropology. '#MadeAtUCL Disruptive Discoveries' talks to UCL researchers answering life's big questions; from green infrastructure to artificial intelligence, space exploration to treating cancer. Find out more about UCL's top Disruptive Discoveries: bit.ly/MadeAtUCL
Interventional Radiologist Dr. Julie Zaetta and Oncologist Dr. Julie Stanton discuss the essentials of building a successful Interventional Oncology program, including the importance of a multidisciplinary approach.
Interventional Oncology with guest Dr. Kevin Kim July 8, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095
Prof Adam talks to ecancertv at NCRI 2014 about interventional oncology which joins surgery, radiation oncology and medical oncology and focuses on minimally invasive image-guided methods to locally destroy tumours using various forms of energy such as radio frequency waves and micro-waves.
Session 15 This week, I speak with Dr. Fayyaz Barodawala, a community-based Interventional Radiologist from Atlanta, Georgia, about his career decisions, what an IR physician does on a daily basis, the struggles and triumphs that come along with his practice and specialties opportunities outside IR and other interesting topics like exclusive hospital contracts and artificial intelligence replacing diagnostics. [01:15] Choosing Interventional Radiology Practicing medicine since 2005, Fayyaz knew he wanted to be an Interventional Radiologist on one particular day during his third day of medical school. He initially found interest in plastic surgery, vascular surgery, and orthopedics. He had exposure to medicine growing up with his parents both physicians but it was on his third year, surgical rotation that he remembered being chewed out after having observed a surgical procedure passively for so long. During that same day, he went to see a family friend how happened to be called in for a pulmonary arteriogram and surprised at how quick the procedure was. At that point, he was considering orthopedics or radiology with the full intention of going into interventional, if he did the latter. What he likes about the field is the fact that you get to do different and relatively short procedures that make a difference and people happy. [04:10] Traits of a Great Interventional Radiologist Fayyaz says the things that make great interventional radiologists are knowledge of imaging and problem-solving. A lot of what he has to do is a lot of problem-solving. There may be defined pathways to do certain things but If they don't go as planned, then you have to improvise a lot. You have to be able to figure out how to accomplish your goal using the tools you have. A running joke during his fellowship was that IR was the last name on the chart so when everybody thinks a procedure is too high-risk for them, they'd call IRs to take care of it. IRs do so much work like put filters in, arterial work, oncologic work, spine work, etc. So they have their hands on a whole bunch of different places but problem-solving and thinking outside the box are good traits to have for Radiology. And of course, you need to know your Anatomy. [06:22] Types of Patients Interventional radiologists treat younger, healthier patients that they might see for as simple as venous access like a PICC or younger women who have heavy menstrual bleeding due to fibroids. They do uterine artery embolization. They treat veins for cosmetic and medical reasons like a vein ablation and sclerotherapy. They also treat older patients with spinal fractures for vertebroplasty or kyphoplasty. They treat a lot of oncologic patients which branches off into its whole own sub or super-specialty, even treating hepatic tumors such radio embolization, chemo embolization, or radiofrequency or microwave ablation or cryoablation. Hence, the see a full spectrum of patients who are younger and healthier to older and very, very sick. [07:32] A Typical Day for an Interventional Radiologist His current practice is less hard core and interventional than he would have liked. Bread and butter for them would be paracentesis, thoracentesis, chest port placement for chemo, various biopsies, vertebral kyphoplasty for spinal fractures. In his latest practice, he had gotten into a lot of pain management procedures such as epidural steroid injections, lumbar puncture, and myelogram. In between, he reads diagnostic imaging. Interventional radiologists do a wide variety of cases. Today, Fayyaz did paracentesis, thoracentesis, fluoroscopy, breast biopsies, and red PET scans. Other days, he could be doing a lot more like nephrostomies, biliary drainage, kyphoplasties. They're also currently ramping up their oncologic work at the new group he's in, doing ablations and radio embolizations that are starting to pick up now. Even if you're a little ADD, you can find stuff that's good because it's not monotonous. On the flip side, they do very heavy-duty cases like TIPS which do not occur as often but these cases could be longer. In their group of 4 IR doctors, they're on call every fourth so once per quarter for a weekend and random days here and there depending on the hospital setup. Fayyaz further says that if there's enough for two or three people to do full time interventional, the more interventional you want to do, the more call you have to take because in their practice, it's not full-time interventional all the time. [12:21] Work-Life Balance and Managing Expectations As reimbursements have fallen, IR does not generate as much income for the practice. Fayyaz thinks it's about managing expectations. You're better being a diagnostic radiologist if you simply want to go in there, punch a clock, and get out. There are also non-traditional options like the outpatient vascular access centers where they do dialysis interventions which are pretty regular hours. Then your work-life balance can be great. Fayyaz would describe his work-life balance as pretty good, starting work at 8 am and usually done by 4:30-4:45 pm. Diagnostic calls can be brutal but interventional calls are not as bad. Again, it's about managing expectations. If you prefer cool cases, then you might get called in the middle of the night for a G.I. bleed for instance. But if you're doing bread and butter cases, work-life balance is fine. [14:25] The Residency Path Back in the mid-90's, there was a time when internship was not required so you go right into Radiology. That changed in around 1995 when they've changed the mandate. The traditional pathway is a year of internship (surgery. medicine, pathology, transitional, pediatrics) then you do four years of Diagnostic Radiology and then one year Interventional Fellowship It's a six-year thing. The direct pathway is for the Diagnostic and Interventional Radiology-enhanced clinical track. However, this is going away in favor of a pure IR residency right now as they shift into a new paradigm that's evolving more quickly. As more and more programs go towards that, you will match into Interventional Radiology directly from medical school, which includes more clinical time, cut down the diagnostic time a bit and increase the interventional time. (The first set of programs was just approved last year. so they're just starting.) This is great if you want to do something interventional but Fayyaz is not sure how this is going to work for the private practices so he has some reservations. He further explained that a lot of these plans are placed by academics which is a really different setup than private practice. It's tough for a private practice doctor that doesn't have a ton of interventional because they're not going to be as versatile. Hence, in huge practice, it's great but in a not-huge practice, that remains to be seen. The new model is to set up your own practice just as a surgeon or cardiologist would, see patients clinically and then bring them to a hospital. But that's probably they're going to end up. In order to compete, you can't have the old model just sitting there waiting for procedures to come to you. You have to market, you have to evaluate patients and do consults which not some of the older guys are used to. [18:14] Matching for Interventional Radiology Competition for interventional radiology goes in phases. As a job, the competition has tightened as more interest is starting to happen in interventional due to the difficulty of outsourcing it. People also enjoy doing procedures so it has been incredibly competitive in the last couple of years, to the point that people are not matching for Interventional Fellowships. To be competitive for matching, you have to be a hard worker and have a mentality of saying yes almost all the time. And if you say yes all the time and then you say no, then people respect your opinion. Be willing to get your butt kicked for a while so you will be ready to handle everything that comes at you. Other things that can make you competitive are being innovative, being able to do problem-solving, knowing the imaging, being clinical, willing to constantly learn new things, and understanding that there are things you don't know so just be able to take in what you can and learn as you go afterwards. Fayyaz doesn't necessarily believe that scores tell everything. It's one tool for weeding but it shouldn't be the only tool. Fayyaz went to a program where research was not a priority but if you're looking at research-heavy programs, it depends on what your goal is. If your goal is academic research and publish, then look for a program that can cultivate and nurture that. If you want to be a work horse, then you want something that gives you more clinical training. During his residency, there were very few Fellows so they had to do a ton as a resident. It's nice to have a highly resident-centric program when you're a resident and a very fellow-heavy program when you're a fellow. Nevertheless, research is important in helping the interventionalist. A lot of procedures are pioneered by radiologists but as they get more commonplace and more routinely and more lucrative, other specialties start snipping away at it so you're going to be experiencing turf battles. For instance, a lot of people might be fighting for a cerebral angiogram which can be done by interventional radiologist or a vascular surgeon, a neurologist, and neurosurgeons. [24:47] Bias Against DOs Fayyaz worked in New York hospital that had a deep Radiology residency DO program and would be joking to them about how MDs couldn't go into the DO programs and DOs could go into the MD program. On a serious note, he doesn't really see any distinct bias but it's there for some other people. [26:50] Special Opportunities for Sub-Specialties Some interventionalists would like to do peripheral arterial but that’s contentious because different specialties have gotten involved and everybody wants to do it thinking it's cool and reimbursements can be very high. Some people work with vascular surgeons and even joined vascular practices. But the big thing right now is Interventional Oncology and that's where everybody wants to get into. It involves stuff like radio embolization, chemotherapies, and various regimens. Other people do Neuro Interventional which typically requires a Neuro Radiology Fellowship and then Neuro IR Some also get involved in Stroke Intervention. There is some overlap between Neuro Intervention and IR next. You can also do Pediatric Interventional Fellowship. [28:48] Working with Primary Care and Other Specialties Speaking of clinical IR and not waiting for people to refer to you, Fayyaz meant not waiting for a vascular surgeon or cardiologist or somebody else to refer to you. Peripheral vascular disease, for example, are marketed successfully by primary care physicians to family practice, internal medicine, pediatrists. He's not sure if they really understand exactly what IRs do which has been a problem for them because they're not aware of the services they offer. IRs hundreds of chest ports and they could probably do even better than surgeons sometimes as backed by evidence. They could do it faster and cheaper. So IRs do more than just that, they do biopsies, spine interventions, peripheral arterial, biliary stuff and those people thought as surgical procedures. They also do fibroid embolization, venous disease, and gastrostomy in so all these things can be done. What feels frustrating is they sometimes feel just as a back up and they're only sought for because no one else is available to do it. It would be nice to have a great relationship between the primary physician and the IR. Check what IRs are doing because you might be surprised what the interventionalist can do for you. Other specialties Interventional Radiologists work the closest with include Oncology, Orthopedics, Hospital/Critical Care. Fayyaz says the best way would be an alliance between vascular surgery and radiology and interventional competing against cardiology. [33:05] Diagnostic Radiologists Replaced with A.I. Interestingly, Fayyaz mentioned that there have been thoughts of merging Diagnostic Radiology and Pathology into one specialty. The argument is that given it's a lot of pattern recognition on the diagnostic side, those should be handled by computers and the physician would be instead be involved in the management. I personally believe that within 20 years, radiologists are going to be replaced with AI for diagnostic purposes. Fayyaz agrees it may come and could be scary. But there is a lot of grey zone for now. If computers could just highlight findings of questionable significance and let somebody go through it then that would be helpful in making their job faster and better. [37:00] Other Special Opportunities Outside of IR Radiologists have a lot of unique opportunities since they interact with a lot of specialties. They can be very strong in administration. Fayyaz adds that IRs are somewhat anchors for the group in the hospital because they're providing a lot of coverage that can't be easily outsourced. Again, it's important to not wait for things to come to you but to be out there somewhat marketing yourself, being available, getting your face shown so people know who you are and getting up there. If you're in the academics, you can get into the consulting industry. [39:37] Exclusive Hospital Contracts & Diagnostic versus Interventional Radiology What he wished he knew before going into Interventional Radiology is that you're being behold into a hospital for contract. One of the difficult things is that as people break off and form their own interventional practices, the model for Radiology is typically within exclusive contract so the group may have an exclusive contract in the hospital. So even if the IR guy is new to the city, you might be able to find a place to do your procedures since the radiology group in the hospital may block you from getting any privileges there. If you want to bring a peripheral arterial case into the hospital for instance, they'll block you from doing it because they would say they have an exclusive contract yet the cardiologist or the vascular surgeon who does the same thing and wants to get into the hospital can come in. Second, Fayyaz recognizes the difficulties in interaction between the diagnostic and interventional physicians because they have to realize that in order to build a good clinical practice, you do need some clinical time. But it can be very hard for the diagnostic people to see that and find that time but they have to realize that builds their credibility. Third, there are options to do some of the interventional stuff not through Interventional Radiology residency or fellowship but other fields can chomp at your toes but that keeps you fresh and innovative. [42:33] The Best and the Worse Things About an IR Fayyaz loves helping people through their tough times and being there to help them and see them get better. He likes that he can calm somebody down and loves how quick the procedures can be and people get to see the results fast. He would love to expand his practice and get into the cosmetic side of IR or expand in Oncology. overall, seeing his patients get better is the most gratifying. The least thing he likes about being an IR is getting dumped on with cases other specialties are not willing to do. As frustrating as it seems, you can't let it get to you. In general, radiologists are happy and they do what they do. They can always find a niche depending on what you really want to do. If he were to choose another specialty again, Fayyaz doesn't actually know considering his interest in plastic surgery. Although Interventional Radiology could still be on top of his list, he could not deny the difficulties and risks related to doing private practice although that could depend on your geographic location. Overall, he likes what he does but some parts can be very frustrating specifically, the exclusive contracts and being behold into a hospital. However, Fayyaz sees that over the next ten years, more and more exclusive contracts will fall and you will get that new model where two or three interventionalists get together to bring cases in and not have a group that blocks you from being in a hospital. [49:25] Last Words from Fayyaz Do what you like and don't try to chase it because you think there will be a job afterwards. If you don't like it, don't do it. Second, try to spend time with somebody in that field or at least talk to them to see what their life is really like. Third, see what life is like after and see if this is something you can really do. Realize that a lot of practices may not be all high-powered cases all the time. Tap into resources to learn more about the kind of procedures we do. You're going to have to weigh money, time off, location, case mix, and with all those together, you would have to find the best mix and adjust the dials to where you can live with something and say this is good. There is no perfect job ever. You don't let people tell you no. If they say no then find a way to do it and give it a shot. Links: MedEd Media Network
Interventional oncology, practiced by interventional radiologists, is one of four parts of a multidisciplinary team approach in the treatment of cancer and cancer related disorders.How does it complement current cancer treatment methods?What type of patients are candidates for interventional oncology?David Tahour, MD is here today to discuss these and other great questions concerning interventional oncology.
Treatment topics covered are Chemo Embolization, Cryo Ablations, Radio Frequency Ablations, and SIRSpheres. (January 2009)
© 2020-2025 Ivy Podcast Discovery LLC
